Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
Evaluation of Safety and Efficacy of Autologous Stromal Vascular Fraction Derived From Denovo Versus Platelet Rich Plasma Enhanced Donner Site in Treatment of Male Androgenic Alopecia
1 other identifier
interventional
40
0 countries
N/A
Brief Summary
Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2024
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2024
CompletedFirst Submitted
Initial submission to the registry
March 9, 2024
CompletedFirst Posted
Study publicly available on registry
March 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2026
ExpectedMarch 22, 2024
March 1, 2024
7 months
March 9, 2024
March 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
hair density
Trichoscopy
at baseline and at 6 month after treatment
hair shaft thickness
TrichoScan
at baseline and at 6 month after treatment
Study Arms (2)
autologous stromal vascular fraction derived from denovo
ACTIVE COMPARATORautologous stromal vascular fraction derived from denovo in male androgenic alopecia
autologous stromal vascular fraction after platelet rich plasma enhanced donner site
ACTIVE COMPARATORautologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia
Interventions
autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Eligibility Criteria
You may qualify if:
- Male patients with androgenic alopecia
You may not qualify if:
- Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.
- Any other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area.
- Any systemic disease as autoimmune disorders , cardiac hepatic and renal patients.
- patients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant lecturer
Study Record Dates
First Submitted
March 9, 2024
First Posted
March 22, 2024
Study Start
March 1, 2024
Primary Completion
October 1, 2024
Study Completion (Estimated)
October 1, 2026
Last Updated
March 22, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share